Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Dermatologic Clinics
- Vol. 33 (1) , 57-71
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Shortcomings of PASI75 and practical calculation of PASI area componentJournal of the American Academy of Dermatology, 2013
- What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literatureJournal of the European Academy of Dermatology and Venereology, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005
- Two Decades Experience of the Psoriasis Disability IndexDermatology, 2005
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trialArthritis & Rheumatism, 2003
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992